BASKING RIDGE, N.J., February 15, 2018 – Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY) (Ipsen), announced Dysport® (abobotulinumtoxinA) data will be presented today in two oral presentations at the annual meeting of the Association of Academic Physiatrists (AAP) being held in Atlanta, February 13-17, 2018. The oral presentations provide the outcomes of multiple Phase 3 studies that evaluated time to retreatment, as well as long-term treatment with Dysport® .
“The data being presented at this year’s AAP meeting indicate that Dysport® provides sustained spasticity relief for both adult and pediatric patients,” said David Cox, Vice President, US Medical Affairs, HEOR & Commercial Regulatory Affairs, Ipsen. “Improved outcomes from long-term therapy along with longer time between injections can be important factors in the management of these conditions, and we’re pleased to share these data to help inform physician and patient treatment decisions.”
In the first oral presentation, results from three randomized, placebo-controlled, double-blind Phase 3 studies of Dysport® evaluating time to retreatment in three patient groups showed that 37 percent of hemiparetic (post-stroke/traumatic brain injury) patients with adult upper limb spasticity (AULS), 20 percent of hemiparetic patients with adult lower limb spasticity (ALLS) and 74 percent of patients with pediatric (at least two years of age) lower limb spasticity (PLLS) due to cerebral palsy did not require reinjection until week 16 or later (Abstract #361196).
Learn more by clicking here